Brian Cosgrove
@itsbcos.bsky.social
Principal Scientist at TuneTX. Alum of the Gersbach Lab @DukeU and the Mauck Lab @Penn BE PhD. Excited about Epigenetics, coffee, and tech.
Excited to share that we received clearance from NZ to begin the clinical trial for our Tune-401 epi-silencer in patients with chronic hepatitis B. We hope that this new approach will be able to chart a new path towards increasing functional cure rates in CHB patients!
endpts.com/new-zealand-...
endpts.com/new-zealand-...
New Zealand clears first clinical trial of epigenetic editing for hepatitis B
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials. Led by Ed Gane at Auckland City Hospital, it's the second HBV genome-altering...
endpts.com
November 19, 2024 at 7:08 PM
Excited to share that we received clearance from NZ to begin the clinical trial for our Tune-401 epi-silencer in patients with chronic hepatitis B. We hope that this new approach will be able to chart a new path towards increasing functional cure rates in CHB patients!
endpts.com/new-zealand-...
endpts.com/new-zealand-...